KRAS and non-small cell lung carcinoma: Two specific KRAS G12C inhibitors, adagrasib and sotorasib, showed significant clinical activity in NSCLC patients harboring such mutation, achieving response rates of 43% and 37% in later treatment lines, respectively.2,3 Despite these promising results, the durability of response remains a concern, as most patients eventually develop resistance and experience disease progression.4 Several mechanisms of resistance to KRAS G12C inhibitors have been identified and broadly categorized into on-target and off-target.